News

As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. Shipment of

EnVivo will continue to research and develop histone deacetylase (HDAC) inhibitors for neurodegenerative disorders such as Huntington’s, Alzheimer’s and Parkinson’s diseases under license from MethylGene. A lead compound

The Office of Generic Drugs, FDA, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Ceftin

Under the terms of the agreement, Dynogen will become a public company through a merger with a subsidiary of Apex Bioventures. As part of the agreement, Dynogen shareholders

The collaboration will focus initially on ligament and tendon repair products that will feature coatings based on BioSET’s proprietary F2A synthetic growth factor technology. The BioSET F2A peptide

The acquisition will expand PPD’s global reach with established offices in both Russia and Ukraine. The acquisition is expected to close in the second quarter of 2008, subject

The Phase I double-blind, placebo-controlled trial has enrolled 30 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily subcutaneous injections of placebo or 40mg, 70mg

Under the terms of the agreement, ACS Biomarker has granted BG Medicine exclusive, worldwide commercial rights to pursue the development, validation, regulatory approval and commercialization of diagnostic tests

David Earp, Geron’s senior vice president of business development and chief patent counsel, said: “The claims in this patent broaden the coverage for our islet protocol beyond the